



KDIGO Controversies Conference on Novel Anemia Therapies in CKD

#KDIGOAnemiaTherapies

Thursday, December 9

12:00pm PST / 3:00pm EST / 8:00pm GMT / 9:00pm CET
(5:00am JST / 7:00am AEDT +1 day)

Introduction: Meeting Overview

(All times EST)

- | | |
|----------------|--|
| 3:00 – 3:10 pm | Welcome & Introductions
John Davis, KDIGO CEO & Wolfgang Winkelmayr, KDIGO Co-Chair |
| 3:10 – 3:20 pm | Conference Overview, Objectives, and Ground Rules
Elaine Ku & David Wheeler, Conference Co-Chairs |

Plenary Session

- | | |
|----------------|--|
| 3:20 – 3:45 pm | HIF Stabilizer Trials in CKD/HD Patients – What Do the Data Really Show?
Jonathan Barratt |
| 3:45 – 3:55 pm | Q&A |
| 3:55 – 4:20 pm | Will We Need to Give Any Iron When We Prescribe HIF Stabilizers?
Jodie Babitt |

4:20 – 4:30 pm	Q&A
4:30 – 5:00 pm	Debate: Are HIF Stabilizers a Viable Alternative to ESAs in the Management of Anemia in CKD Iain Macdougall & Jay Wish
5:00 – 5:10 pm	Q&A
5:10 – 5:30 pm	Group Discussion
5:30 pm	Preparations for Day 2 & Wrap Up Elaine Ku & David Wheeler, Conference Co-Chairs

Friday, December 10


12:00pm PST / 3:00pm EST / 8:00pm GMT / 9:00pm CET
(5:00am JST / 7:00am AEDT +1 day)

Preliminary Breakout Group Reports & Discussion

(All times EST)

3:00 – 3:05 pm	Opening Remarks Elaine Ku & David Wheeler, Conference Co-Chairs
3:05 – 3:30 pm	Group 1: Therapeutic use of HIF-PH inhibitors vs. current therapies in anemia management: CKD patients not on dialysis treatment Lucia Del Vecchio & Nav Tangri
3:30 – 3:40 pm	Q&A
3:40 – 4:05 pm	Group 2: Therapeutic use of HIF-PH inhibitors vs. current therapies in anemia management: CKD patients treated with dialysis Kirsten Johansen & Masaomi Nangaku
4:05 – 4:15 pm	Q&A

4:15 – 4:25 pm	Break
4:25 – 4:50 pm	Group 3: Safety profile of HIF-PH inhibitors in CKD anemia management Sushrut Waikar & Andrzej Wiecek
4:50 – 5:00 pm	Q&A
5:00 – 5:25 pm	Group 4: Pathophysiology of HIFs and effects beyond hemoglobin Kai-Uwe Eckardt & Volker Haase
5:25 – 5:35 pm	Q&A
5:35 – 6:00 pm	Full Group Discussion
6:00 pm	Preparations for Day 3 & Wrap Up Elaine Ku & David Wheeler, Conference Co-Chairs



Saturday, December 11

12:00pm PST / 3:00pm EST / 8:00pm GMT / 9:00pm CET
(5:00am JST / 7:00am AEDT +1 day)

Breakout Session

(All times EST)

3:00 - 5:00 pm	Group 1: Therapeutic use of HIF-PH inhibitors vs. current therapies in anemia management: CKD patients not on dialysis treatment
4:00 - 6:00 pm	Group 2: Therapeutic use of HIF-PH inhibitors vs. current therapies in anemia management: CKD patients treated with dialysis
3:00 - 5:00 pm	Group 3: Safety profile of HIF-PH inhibitors in CKD anemia management

3:00 - 5:00 pm Group 4: Pathophysiology of HIFs and effects beyond hemoglobin

Sunday, December 12

12:00pm PST / 3:00pm EST / 8:00pm GMT / 9:00pm CET
(5:00am JST / 7:00am AEDT +1 day)

Final Breakout Group Reports & Discussion

(All times EST)

3:00 – 3:05 pm	Opening Remarks Elaine Ku & David Wheeler, Conference Co-Chairs
3:05 – 3:30 pm	Group 4: Pathophysiology of HIFs and effects beyond hemoglobin Kai-Uwe Eckardt & Volker Haase
3:30 – 3:40 pm	Q&A
3:40 – 4:05 pm	Group 3: Safety profile of HIF-PH inhibitors in CKD anemia management Sushrut Waikar & Andrzej Wiecek
4:05 – 4:15 pm	Q&A
4:15 – 4:25 pm	Break
4:25 – 4:50 pm	Group 2: Therapeutic use of HIF-PH inhibitors vs. current therapies in anemia management: CKD patients treated with dialysis Kirsten Johansen & Masaomi Nangaku
4:50 – 5:00 pm	Q&A
5:00 – 5:25 pm	Group 1: Therapeutic use of HIF-PH inhibitors vs. current therapies in anemia management: CKD patients not on dialysis

treatment
Lucia Del Vecchio & Nav Tangri

5:25 – 5:35 pm

Q&A

5:35 – 6:00 pm

Full Group Discussion

6:00 pm

Closing Remarks & Next Steps
Elaine Ku & David Wheeler, Conference Co-Chairs